Page last updated: 2024-12-04

oxaluric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

oxaluric acid : A 2-oxo monocarboxylic acid that is amino(oxo)acetic acid substituted by a carbamoylamino group at the nitrogen atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID456
CHEBI ID16582
SCHEMBL ID899896
MeSH IDM0052823

Synonyms (26)

Synonym
CHEBI:16582
(carbamoylamino)(oxo)acetic acid
onooxalylurea
ureido(oxo)acetic acid
oxalureate
oxaluric acid
monooxalylurea
585-05-7
C00802
FT-0693010
2-(carbamoylamino)-2-oxoacetic acid
AKOS006273229
acetic acid, ((aminocarbonyl)amino)oxo-
carbamoyloxamic acid
SCHEMBL899896
UGC ,
acetic acid, [(aminocarbonyl)amino]oxo-
UWBHMRBRLOJJAA-UHFFFAOYSA-N
[(aminocarbonyl)amino](oxo)acetic acid #
3-oxaluric acid
DTXSID00207214
carbamoylamino(oxo)acetic acid
oxalursaure
2-oxo-2-ureidoacetic acid
Q27101984
carbamoyloxalamidsaeure
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Allantoin Degradation (Anaerobic)518

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (58.33)18.7374
1990's1 (8.33)18.2507
2000's4 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.87 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index168.36 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (67.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]